Who are docetaxel and cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nab-paclitaxel，Cisplatin, Paclitaxel, Carboplatin, Four-Weekly TC Consolidation Chemotherapy, Paclitaxel and carboplatin, Paclitaxel + Carboplatine, Docetaxel/Cisplatin control.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-and-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

docetaxel and cisplatin — Competitive Intelligence Brief

docetaxel and cisplatin (docetaxel and cisplatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (taxane + platinum agent). Area: Oncology.

marketed Chemotherapy combination (taxane + platinum agent) Microtubules (docetaxel); DNA (cisplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

docetaxel and cisplatin (docetaxel and cisplatin) — Sanofi. Docetaxel and cisplatin is a chemotherapy combination that kills cancer cells by disrupting microtubule dynamics and causing DNA damage through platinum-induced crosslinks.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
docetaxel and cisplatin TARGET	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	Queensland Centre for Gynaecological Cancer	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)
Four-Weekly TC Consolidation Chemotherapy	Four-Weekly TC Consolidation Chemotherapy	Jiangsu Cancer Institute & Hospital	phase 3	Chemotherapy combination (taxane + platinum agent)
Paclitaxel and carboplatin	Paclitaxel and carboplatin	Chinese Academy of Medical Sciences	phase 3	Chemotherapy combination (taxane + platinum agent)	β-tubulin (paclitaxel); DNA (carboplatin)
Paclitaxel + Carboplatine	Paclitaxel + Carboplatine	Intergroupe Francophone de Cancerologie Thoracique	phase 3	Chemotherapy combination (taxane + platinum agent)	β-tubulin (paclitaxel); DNA (carboplatin)
Docetaxel/Cisplatin control	Docetaxel/Cisplatin control	Spanish Lung Cancer Group	phase 3	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (taxane + platinum agent) class)

AstraZeneca · 1 drug in this class
Chinese Academy of Medical Sciences · 1 drug in this class
Intergroupe Francophone de Cancerologie Thoracique · 1 drug in this class
Jiangsu Cancer Institute & Hospital · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Queensland Centre for Gynaecological Cancer · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Sanofi · 1 drug in this class
Spanish Lung Cancer Group · 1 drug in this class
Yang Jianjun, PhD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). docetaxel and cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-and-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab